Immunotherapy for Oesophageal Cancer — Who It Is Actually For

Most people with oesophageal cancer in India are not candidates for immunotherapy. It is considered mainly when the cancer is advanced or has spread, when it has returned after treatment, or when tissue removed at surgery after chemoradiation still contained cancer. Disease that can still be treated with curative intent is treated with chemoradiation and surgery.

Eligibility is confirmed on tissue and on examination, never from a scan report alone. If you were told “you can take immunotherapy” without a biopsy-confirmed type and a biomarker result, ask what that advice was based on.

Both, depending on the setting. As the first treatment for advanced or metastatic oesophageal cancer it is usually added to chemotherapy. After squamous cell disease has progressed on platinum-based chemotherapy it may be given on its own. In the adjuvant setting after chemoradiation and surgery, it is given on its own.

Guidance changes, and it changes faster in this cancer than in most. The positions above reflect NCCN and ESMO oesophageal guidance current as of August 2026, and are applied through our tumour board rather than read off a printout.

The aim is to shrink the cancer or hold it in check. A minority of patients respond. Response rates for checkpoint-inhibitor immunotherapy given on its own in previously treated oesophageal squamous cancer sit broadly in the 15–20% range in NCCN and ESMO guidance current in August 2026, and are higher where PD-L1 expression is strong.

• A response means the cancer shrinks or stops growing. It is judged on scans, not on how you feel in week two. In some of the patients who respond, that control lasts a long time. In others it does not.
• Most patients do not respond. If the scan shows the cancer is growing, immunotherapy is stopped and the plan changes — chemotherapy, radiation for symptom relief, or supportive care. That is a change of plan, not a failure on your part.
• PD-L1 shifts the odds, it does not decide the outcome. Stronger expression is associated with a higher chance of response. Some patients with strong expression still do not respond, and some with weak expression do.
• Swallowing and weight belong in the same conversation. Ask what the plan is for eating, not only what the treatment is meant to do to the tumour. In oesophageal cancer the two cannot be separated.
• Nobody can tell you in advance which group you are in. A doctor who promises you will respond is not describing this treatment accurately.

We deliberately do not put survival figures against this decision on a web page. Those numbers depend on your type, stage, fitness, nutrition and prior treatment, and they belong in a 45-minute consultation with your own reports open in front of you — not in a paragraph written for everybody.

Checkpoint-inhibitor immunotherapy does not attack the tumour directly. It blocks a signal that cancer cells use to switch off the immune cells sent to kill them. Releasing that brake lets your own T-cells recognise and attack the cancer, which is why the effect appears more slowly than chemotherapy’s.

Oesophageal squamous cancers are relevant candidates for two reasons. Tumours driven by years of tobacco, areca nut and alcohol exposure carry a heavy load of genetic damage, which can make them more visible to the immune system. Many also express PD-L1, the protein that carries the “stand down” signal — which is exactly what this treatment is designed to interrupt.

Adenocarcinoma of the lower food pipe and the gastro-oesophageal junction behaves differently and is often planned along the stomach pathway rather than the squamous one. If your report names the junction or the stomach, read immunotherapy for stomach and gastro-oesophageal cancer alongside this page. A tumour that has been driven by decades of tobacco also raises a second question, covered in tobacco use and immunotherapy response.

Because the mechanism is immune, so are the side effects. Inflammation can appear in the skin, bowel, thyroid, liver, lungs, heart or adrenal glands. Reported early, most are manageable. That trade-off should be explained to you before you consent, not afterwards.

Eligibility is worked out in a fixed sequence: confirm the type on tissue, test that tissue for the relevant biomarkers, assess your nutrition and general fitness, review your autoimmune and steroid history, then take the whole picture to a tumour board. No single test decides it, and no step is skipped to save time.

1. 1

   Confirm the diagnosis and the type on tissue

   Biopsy slides are re-read by a pathologist. Squamous cell carcinoma and adenocarcinoma of the food pipe are separated here, because that single line on the report changes the whole pathway. Immunotherapy is never planned from a scan report alone.

2. 2

   Test the tissue for the biomarkers that matter

   PD-L1 expression is reported as a combined score, and MSI or mismatch-repair status is checked. For junction and adenocarcinoma cases, HER2 status is usually added. None of these gives a yes-or-no answer on its own, but together they shape whether immunotherapy is used, and whether it is used with chemotherapy or alone.

3. 3

   Assess nutrition, weight and swallowing

   This step carries more weight in oesophageal cancer than in almost any other. If you cannot swallow enough to hold your weight, that is addressed first — with a dietitian, and where needed a stent or a feeding tube — because starting any systemic treatment in a poorly nourished patient goes badly.

4. 4

   Review autoimmune history, steroids and other conditions

   Rheumatoid arthritis, thyroid disease, psoriasis, inflammatory bowel disease, past transplant, ongoing high-dose steroids and uncontrolled infection including tuberculosis are all raised here. Some of these rule immunotherapy out. Others simply mean closer monitoring.

5. 5

   Tumour board review, then a written plan and a cost estimate

   Medical, surgical and radiation oncologists review the case together before anything is offered — not one doctor’s opinion. You then receive a written plan and a clear estimate, so the money conversation happens before the first cycle rather than after it. All costs are indicative, as of August 2026.

Immunotherapy at CION is given as day care. You come in, the infusion runs over roughly 30 to 60 minutes, you are observed afterwards, and you go home the same day. Cycles repeat every two, three or six weeks. Blood tests are done before each cycle, and scans decide whether it continues.

• Day-care infusion, no admission — a routine cycle does not need an overnight stay. Bring someone with you for the first cycle.
• Bloods before every cycle — thyroid, liver, kidney function and blood counts are checked each time, because immune side effects often show on a blood test before you feel them.
• Response-assessment scans — PET-CT for response assessment is coordinated at partner imaging centres, not performed at CION. We arrange it, read it with you, and use it to decide whether to continue.
• Eating and weight are managed alongside the treatment — a dietitian is part of the plan from the start, not called in after weight has been lost. The same principles apply as in eating and nutrition on immunotherapy for head and neck cancer, where swallowing is the shared problem.
• Report new symptoms the same day — new diarrhoea, a rash, breathlessness, chest pain, severe tiredness or a fast heartbeat go to us immediately, not to the next visit. Call 1800 202 8726 if something changes between cycles.
• Tell every other doctor you are on immunotherapy — including any emergency doctor. Immune side effects are easily mistaken for ordinary infections.

Immunotherapy is administered as day care at CION centres. Response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or other cell therapies; where such treatment is being considered, we say so and refer.

If immunotherapy has been raised for your oesophageal cancer, these companion pages cover the questions that usually follow — the neighbouring pathway at the junction and stomach, eating through treatment, and what tobacco has to do with any of it.

• Immunotherapy for Stomach and Gastro-Oesophageal Cancer — read this if your report names the gastro-oesophageal junction or the stomach, because that pathway is planned differently.
• Eating and Nutrition on Immunotherapy for Head and Neck Cancer — the practical swallowing, weight and feeding guidance that applies just as squarely to a narrowed food pipe.
• Tobacco Use and Immunotherapy Response — what tobacco does to the tumour, what continuing to use it does during treatment, and why we ask.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, delivered and monitored across our centres, and who decides.

One Conversation Can Settle the Question

Whether immunotherapy applies to you takes a tissue diagnosis, a biomarker result and an honest discussion — not a search result. Bring your reports and we will go through them with you.